3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
No longer available
2
Withdrawn
1
Not yet recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Lymphoma, Large B-Cell, Diffuse
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Interventions
Cyclophosphamide
13
Peripheral Blood Stem Cell Transplantation
9
Methotrexate
9
Cytarabine
9
fludarabine phosphate
8
fludarabine
8
Radiotherapy
7
Vincristine
5
Cyclosporine
5
Whole-Body Irradiation
4
Prednisone
4
Mycophenolic Acid
4
Melphalan
4
Filgrastim
4
Etoposide
4
Busulfan
4
asparaginase erwinia chrysanthemi recombinant
3
Tacrolimus
3
Sirolimus
3
Dasatinib
3
Cord Blood Stem Cell Transplantation
3
Bortezomib
3
Asparaginase
3
prednylidene
2
pegaspargase
2
ixazomib
2
deltacortene
2
blinatumomab
2
Thiotepa
2
Therapeutics
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Precursor Cell Lymphoblastic Leukemia-Lymphoma
×
navitoclax
×
Clear all
NCT05740449
2024-06-21
HEM-iSMART A
Princess Maxima Center for Pediatric Oncology
Phase 1/2
Withdrawn